Immuneering Corporation is a clinical-stage biotechnology company focused on developing oncology therapies for patients with cancers driven by dysregulated cell-signaling pathways. The company is headquartered in Cambridge, Massachusetts, and concentrates its research on a proprietary class of small-molecule drugs known as Deep Cyclic Inhibitors. These medicines are designed to selectively and intermittently target components of the MAPK signaling pathway, with the aim of limiting tumor adaptation while maintaining tolerability for patients. Immuneering Corporation’s lead programs target MAPK pathway-driven tumors, including difficult-to-treat solid cancers such as pancreatic cancer. Its experimental therapies are being evaluated as monotherapies and in combination with standard chemotherapies in multiple clinical studies. By focusing on mechanism-based design and precision targeting of oncogenic signaling, Immuneering Corporation plays a specialized role in the oncology drug development landscape, working with clinicians and research centers to advance potential new treatment options for patients with advanced malignancies.